Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Jabil Inc (JBL) Price & Performance

Bristol-Myers Squibb CoTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Jabil Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.68 (market cap $129.94B), while Jabil Inc trades at $368.45 (market cap $37.37B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.5× Jabil Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BMYJBL
Market Cap
$129.94B$37.37B
Sector
HealthTechnology
52-Week High
$65.89$385.50
52-Week Low
$42.60$192.49
Enterprise Value
$163.92B$39.90B
Dividend Yield
3.96%0.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.

BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.

Jabil Inc

Jabil (JBL) trades at $366.10, up 8.75% in 24 hours, reflecting strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with a consensus price target of $448.29, indicating 22% upside. Recent earnings beats and projected AI revenue growth to over $20 billion by fiscal 2027 (UBS, August 11, 2026) support optimism, though high P/E of 44.63 and thin net margins near 2.6% warrant caution.

Outlook is positive with AI-driven expansion, but risks include valuation sensitivity and competitive pressures. Investment appeal hinges on execution of growth forecasts, while volatility may arise from macroeconomic shifts or supply chain disruptions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

Read more on JBL